The online version of this article (doi:10.1007/s00401-017-1738-2) contains supplementary material, which is available to authorized users.
Cerebral white matter lesions (WML) encompass axonal loss and demyelination, and the pathogenesis is assumed to be small vessel disease (SVD)-related ischemia. However, WML may also result from the activation of Wallerian degeneration as a consequence of cortical Alzheimer’s disease (AD) pathology, i.e. hyperphosphorylated tau (HPτ) and amyloid-beta (Aβ) deposition. WML seen in AD have a posterior predominance compared to non-demented individuals but it is unclear whether the pathological and molecular signatures of WML differ between these two groups. We investigated differences in the composition and aetiology of parietal WML from AD and non-demented controls. Parietal WML tissue from 55 human post-mortem brains (AD, n = 27; non-demented controls, n = 28) were quantitatively assessed for axonal loss and demyelination, as well as for cortical HPτ and Aβ burden and SVD. Biochemical assessment included Wallerian degeneration protease calpain and the myelin-associated glycoprotein (MAG) to proteolipid protein (PLP) ratio (MAG:PLP) as a measure of hypoperfusion. WML severity was associated with both axonal loss and demyelination in AD, but only with demyelination in controls. Calpain was significantly increased in WML tissue in AD, whereas MAG:PLP was significantly reduced in controls. Calpain levels were associated with increasing amounts of cortical AD-pathology but not SVD. We conclude that parietal WML seen in AD differ in their pathological composition and aetiology compared to WML seen in aged controls: WML seen in AD may be associated with Wallerian degeneration that is triggered by cortical AD-pathology, whereas WML in aged controls are due to ischaemia. Hence, parietal WML as seen on MRI should not invariably be interpreted as a surrogate biomarker for SVD as they may be indicative of cortical AD-pathology, and therefore, AD should also be considered as the main underlying cause for cognitive impairment in cases with parietal WML.
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY et al (2013) Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34:457–468 PubMed
Fairbairn AF, Gould N, Kendall T, Ashley P, Bainbridge I, Bower L, et al. (2007) Therapeutic interventions for people with dementia. In: Dementia: A NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. The British Psychological Society and Gaskell Leicester UK, pp 164–216
Litchfield S, Nagy Z (2001) New temperature modification makes the Bielschowsky silver stain reproducible. Acta Neuropathol 101:17–21 PubMed
Skrobot OA, Attems J, Esiri M, Hortobagyi T, Ironside JW, Kalaria RN et al (2016) Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment. Brain 139:2957–2969 CrossRef
Smallwood A, Oulhaj A, Joachim C, Christie S, Sloan C, Smith AD et al (2012) Cerebral subcortical small vessel disease and its relation to cognition in elderly subjects: a pathological study in the Oxford Project to Investigate Memory and Ageing (OPTIMA) cohort. Neuropathol Appl Neurobiol 38:337–343 CrossRefPubMed
Thal DR, von Arnim CA, Griffin WS, Mrak RE, Walker L, Attems J et al (2015) Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies. J Neural Transm (Vienna) 122:1007–1018 CrossRef
- Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease
Kirsty E. McAleese
Elisa L. J. Moya
Sean J. Colloby
Alan J. Thomas
Ian G. McKeith
Charles De Carli
- Springer Berlin Heidelberg